Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management
Obesity patients earning over $250,000 annually are 72% more likely to take a GLP-1 than those earning $50,000 or less (6.8% vs
Once you get started on the medication, your healthcare provider may slowly increase your dosage every 4 weeks
Fluorinated (-CF x ) and methylated (-CH 3 ) functional surfaces have low surface energy and are not energetically favorable for water to interact with, leading to a hydrophobic surface with high water contact angles [1]
Why this matters: RMS can have a profound impact on daily life, with relapses and disease progression often leading to disability
GLP-1 Receptor Agonist Market Segmentation By Product Outlook (Revenue, USD Billion, 20212034) Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Victoza Zepbound Others By Application Outlook (Revenue, USD Billion, 20212034) Type 2 Diabetes Mellitus Obesity By Route of Administration Outlook (Revenue, USD Billion, 20212034) Parenteral Oral By Distribution Channel Outlook (Revenue, USD Billion, 20212034) Hospital Pharmacies Retail Pharmacies Online Pharmacies By Regional Outlook (Revenue, USD Billion, 20212034) North America US Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Receptor Agonist Market Report Scope Source: Polaris Market Research Analysis GLP-1 Receptor Agonist Market FAQ's The global market size was valued at USD 61.89 billion in 2025 and is projected to grow to USD 257.12 billion by 2034
